Trial Profile
Cetuximab in combination with S-1 in Treating Patients With Metastatic or Unresectable Head and Neck Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 01 Oct 2016 Status changed from not yet recruiting to completed.
- 08 Apr 2013 New trial record